Johanna Holldack

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018.

Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.

Borean Pharma ApS provides biopharmaceuticals drugs and protein engineering services. Its two main components of technology platform are CTLD library technology and trimerisation technology. The company was founded by Hans Christian Thøgersen and Michael Etzerodt in 1997 and is located in Aarhus, Denmark.

Deutsche Krebshilfe gGmbH is a non-profit organization that fights against cancer by supporting various projects through donations. The non-profit company is based in Bonn, Germany and was founded in 1974 by Mildred Scheel. The German company provides information on funding projects, the origin and use of funds, and other relevant data in their annual report. The company encourages people to donate to their cause and provide answers to frequently asked questions about donations. The CEO is Gerd Nettekoven.

Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland.